SLGL Sol-Gel Technologies Ltd

Sol-Gel to Present at Upcoming Healthcare Investor Conferences

Sol-Gel to Present at Upcoming Healthcare Investor Conferences

NESS ZIONA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the Company will present at the following upcoming investor conferences.

Jefferies Virtual Healthcare Conference

Speakers:   Dr. Alon Seri-Levy, Chief Executive Officer
 Gilad Mamlok, Chief Financial Officer
 John Vieira, U.S. Head of Commercialization
Date: June 2, 2020
Time:     11:00 am Eastern Time



Raymond James Human Health Innovation Conference

Speaker:Dr. Alon Seri-Levy, Chief Executive Officer
Date: June 18, 2020
Time:11:40 am Eastern Time

Sol-Gel’s senior management team will provide an overview of the Company and give a business update. Live webcasts of the presentations will be available under the “Events and Presentations” in the investors section of the Company’s website at . An archived webcast recording of the events will be available on the website for approximately 30 days post presentation.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit .

For further information, please contact:

Sol-Gel Contact:

Gilad Mamlok

Chief Financial Officer

Investor Contact:

Lee M. Stern

Solebury Trout

Source: Sol-Gel Technologies Ltd.

 

EN
27/05/2020

Underlying

SLGLSol-Gel Technologies Ltd

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sol-Gel Technologies Ltd

 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Cor...

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Patient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210 for Darier disease is ongoingSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S. for a total consideration of $16 million to be received during 2025Following recent transactions, Sol-Gel’s cash runway is expected to extend into the first quarter of 2027 NESS ZIO...

August 15, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Reports First Quarter 2025 Results

Sol-Gel Reports First Quarter 2025 Results NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same p...

May 23, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Announces Reverse Share Split

Sol-Gel Announces Reverse Share Split NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the “Company”) (NASDAQ: SLGL), a clinical-stage dermatology company, today announced a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, par value NIS 0.1 per share (the “Ordinary Shares”), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders’ approval for the Reverse Split at a ratio of between 2:1 and 10:1 at a special meetin...

May 1, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO®...

Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S. Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial...

April 17, 2025 1 EN
 PRESS RELEASE
Free
SLGL Sol-Gel Technol...

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq M...

Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s ("Nasdaq") minimum bid price ...

November 20, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch